Issue 24 | 2016
Get instant access to latest e-book

latest newsRead more...

22

Jul 2016

QuVa Pharma Acquires Biotech Pharmaceutical Facility in New Jersey

QuVa Pharma Inc a recently formed national platform for sterile compounding pharmacy services today announced it has signed an agreement to acquire an FDA approved biotech pharmaceutical facility in New Jersey QuVa Pharma currently operates two Texasbased B registered manufacturing facilit..

22

Jul 2016

Amgen, Allergan biosimilar found as effective as Roche cancer drug

Amgen Inc and Allergan Plc said their copycat version of Roche Holding AGs blockbuster cancer treatment Herceptin was found as effective as the original in a latestage study There were no clinically meaningful differences in data gathered from patients given Herceptin and the copycat version ABP to treat a type of early breast cancer said Sean Ha..

21

Jul 2016

Galenica to buy Relypsa to strengthen its unit Vifor Pharma

Galenica will pay per share in cash or a total of approximately billion Galenica to acquire Relypsa to strengthen its business unit Vifor Pharma Vifor Pharma will gain a fullyintegrated commercial organisation in the US and significantly strengthen its presence in the US cardiorenal market Source reuterscom ..

21

Jul 2016

Roche core EPS ahead of market view on drug sales

Switzerlands Roche surpassed market expectations for core net income per share in the first six months of the year led by drugs such as new asthma treatment Xolair and established breast cancer medicine Herceptin Core earnings per share which are adjusted for certain items rose percent to Swiss francs where analyst..

eventsRead more...

25 - 27

Jul 2016

3rd Annual Advanced API Convention

UBM India
The Westin Mumbai Garden City

22

Jul 2016

22

Jul 2016

22

Jul 2016

QuVa Pharma Acquires Biotech Pharmaceutical Facility in New Jersey

SUGAR LAND Texas July PRNewswire QuVa Pharma ..

TOP ARTICLES

knowledge bank

  • interviews

    Datwyler Pharma Packaging

    Senior Manager Global Scientific Affairs
    Renaud Janssen, Ph.D. is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging. He frequently presents on international conferences on subjects related to elastomeric and aluminium/plastic closures for pharm..

  • Articles

    When Orphan Drugs Make All the Difference

    Orphan drugs those medications that are typically produced in small quantities for limited patient populations are growing in importance worldwide Once largely considered too costly to produce given the limited number of patients affected by a particular disease new technology and new breakthroughs in biopharma have changed the landscape allowing more orphan drugs to be produced than ever before t..

  • Research Insights

    Progress And Perspectives On Targeting Nanoparticles For Brain Drug Delivery

    Abstract Due to the ability of the bloodbrain barrier BBB to prevent the entry of drugs into the brain it is a challenge to treat central nervous system disorders pharmacologically The development of nanotechnology provides potential to overcome this problem In this review the barriers to braintargeted drug delivery are reviewed including the BBB bloodbrain tumor barrier BBTB and nosetobrain barrier Delivery strategies are focused on overcoming ..

editorial Section

  • Competing on Alignment

    SWOT is both the most powerful and least understood strategic management tool Used correctly it translates the outputs of many other market analyses into a small number of key issues..

  • Future Trends in Ion Channel and Solute Transporter Drug Discovery

    Gene family members of the ion channel and solute transporter SLC families represent both historical targets of pharmaceutical significance and serve as exciting opportunities for current and future therapeutic development The common property of ion movement for many of the SLCs lends itself to considering platforms used in ion channel research to enable early drug discovery In addition the convergence of advances in both genetic analysis and assay technology bodes well for the identification of the next generation of ion channel and transporterbased drugs in the near future..

  • Issues & Concerns in Conducting Clinical Trials in India

    Issues like approval delays deficiencies of functioning of CROs and other stake holders liabilities and compensation to injured subjects insurance issues etc still remain in India which has made multinational companies to rethink on opting for India to conduct clinical trials in India recently There is a need for a law to ensure that the people who undergo clinical trials are not exploited and should be well informed about risk as well to provide..

  • Innovation Challenges in Manufacturing

    Most firms in the pharmaceutical industry think globally to expand demand for their products There are amenities from which firms leverage to launch a strategy to gain global market share These amenities include the regulatory dimension which helps reassign resources within and outside the firm..

  • Quality by Design

    The article presents a novel approach to applying Quality by Design QbD principles to the development of analytical methods Common critical parameters in HPLC gradient time temperature pH of the aqueous eluent and stationary phase are evaluated within the Quality by Design framework It is useful for the robust analytical method development and Design Space optimisation..

  • Peptides Remain a Growth Story

    Cloud solutions offer immediate returns in improving operational performance and reducing costs Multiple approaches to cloud solutions will be needed to satisfy life science industry needs complicating the development of a coherent cloud strategy..

TOP